News

Filter by Category
Filter by Year

Synaffix Wins World ADC Award for Poster on Efficacy and Tolerability Data on SYNtecan E™-Based ADCs

  • Winning scientific poster shows complete tumor regression and high tolerability of SYNtecan E™ based ADCs
  • SYNtecan E™ linker-payload is developed by Synaffix based on the potent DNA topoisomerase 1 inhibiting exatecan
  • Additionally, Synaffix was awarded ‘Runner-Up’ for the 2021 Best ADC Platform Technology (Winner in 2020)

AMSTERDAM, NETHERLANDS – 28 October 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index today announces that the Company was awarded Best Poster at Hanson Wade’s 2021 World ADC Conference. Separately, Synaffix was also awarded ‘Runner-Up’ for the Best ADC Platform Technology.

New data presented in the winning poster, titled: “GlycoConnect™ ADCs Based on Topoisomerase 1 Inhibitor Exatecan (SYNtecan E™) Show Excellent In Vivo Efficacy and Tolerability Data” demonstrated complete tumor regression and high tolerability of SYNtecan E™ based ADCs, and underscores the ability of Synaffix’s technologies to enable best-in-class, next generation ADCs.

This marks the fifth year that Synaffix’ groundbreaking ADC platform technology has been acknowledged at the World ADC Awards ceremony as industry-leading, by a judging panel of world-renowned ADC experts.  The 2021 finalists were shortlisted through a voting pool of over 2,500 individuals, with a panel of distinguished, independent industry experts from across the ADC field assessing each finalist to decide the winners.

Prof. Floris van Delft, CSO of Synaffix, said: “The SYNtecan E™ linker-payload represents a transformational innovation that emerged from our own laboratories here in the Netherlands.  This appreciation by our industry peers serves as yet another testament to the high-quality science that underlies our broader ADC platform technology offering and we look forward to continuing the close collaboration with our various partners as this linker-drug enters the clinical development phase.”

Corporate
Join Mailing List

Copyright Synaffix BV 2021. All Rights Reserved

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace™ Polar Spacer

Forming an integral part of every toxSYN™ linker-payload, HydraSpace™ bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace

GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect™

toxSYN™ Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
toxSYN™
Linker-Payload
Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase inhibition Exatecan
2. SYNeamicin D™*DNA
damaging
Calicheamicin γ1I
3. SYNeamicin G™*N-glycyl calicheamicin γ1I
4. SYNstatin E™Microtubule
inhibition
MMAE
5. SYNstatin F™ MMAF
6. SYNtansine™ maytansinoid**

* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™

** N-6-aminohexanoyl-maytansine (Ahx-maytansine)